There is no evidence of additional benefit for the Alzheimer’s drug lecanimab

The independent German Institute for the Quality and Efficiency of Health Services (IQWiG) in Cologne showed in a recent evaluation that no additional benefit could be demonstrated for lecanimab compared to the current standard of treatment in Germany.And…

• For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and Related